Arbor Biotechnologies
Winston Yan, MD PhD, is a co-founder and head of translational strategy at Arbor Biotechnologies, focusing on advancing genome editing for serious genetic diseases. As the founding president and board member of N=1 Collaborative, Winston Yan emphasizes the development of personalized treatments for ultra-rare diseases. Previously, Winston Yan contributed to the Broad Institute of MIT and Harvard as a graduate student, addressing translational challenges in CRISPR technology and enhancing its therapeutic applications. Additional experience includes roles as an interactive developer for an online neuroscience course at Harvard and as a resident tutor, where Winston Yan advised students on academic and career pathways. Educational qualifications include a Doctor of Philosophy in Biophysics and a Doctor of Medicine from Harvard University, alongside an undergraduate degree in Physics from the same institution.
Arbor Biotechnologies
2 followers
Arbor Biotechnologies is an early stage life sciences company pushing the boundaries of biodiscovery. Arbor’s platform employs a diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for improving human health and sustainability.